The FDA approved single-agent treatment with pembrolizumab in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy and positive tumor PD-L1 expression (CPS score > 1%) in 2018 [95]. The gene discussed is CD274; the disease is cervical cancer.